OVERVIEW
Happy Saturday

Welcome to the Stocktwits Top 25 Newsletter this week!

Last week, many of you noticed our numbers were out of whack, so this week we are starting over: fresh lists of the top performers so far this year. We are including the comparative momentum meter to show the total return if you had already owned these stocks so far this year, and how they would have performed.

This year, expect better graphs! We are working on back end tricks to make these momentum lists better than ever, so stay tuned!

The Stocktwits Top 25 reports the 25 best-performing stocks in the S&P 500, Nasdaq 100, and Russell 2000 year to date and tracks their performances over time. To help you understand this data further, check out our FAQ page, and feel free to reach out if you have questions!

Here are the Stocktwits Top 25 Lists for this week:

S&P 500
ST Top 25 S&P 500 💪

The S&P 500 Top 25 list came up 4.87% compared to the weekly S&P 500 index -0.35%

PRESENTED BY

Introducing the first AI-native CRM

Connect your email, and you’ll instantly get a CRM with enriched customer insights and a platform that grows with your business.

With AI at the core, Attio lets you:

• Prospect and route leads with research agents

• Get real-time insights during customer calls

• Build powerful automations for your complex workflows

Join industry leaders like Granola, Taskrabbit, Flatfile and more.

👉 Try Attio Pro for free

*3rd Party Ad. Not an offer or recommendation by Stocktwits. See disclosure here. 

NASDAQ 100
The Large-Cap Nasdaq 100 🤖

The Nasdaq 100 Top 25 list performed 2.42% compared to the weekly Nasdaq 100 index 0.30%

RUSSELL 2000
The Growth-Centric Russell 2000 🦐

The Russell 2000 Top 25 list was 19.23% compared to the weekly Russell 2000 index -0.32%

Top Dawg Of The Week 🐶

The Top 25 list's Top Dawg was $CRVS ( ▼ 8.33% ) , climbing an insane 211%!

Corvus Pharmaceuticals experienced an explosive rally this week primarily due to breakthrough clinical trial data for soquelitinib, its oral treatment for atopic dermatitis (eczema). On Tuesday, the company reported that patients in its Phase 1 "Cohort 4" study saw a 72% reduction in eczema severity after eight weeks of treatment, significantly outperforming the placebo group. This data was viewed by analysts as "best-in-class," suggesting the pill could eventually compete with or surpass leading injectable biologics like Dupixent.

The massive surge in share price, which at one point saw the stock more than double, allowed the company to immediately capitalize on the momentum with a major capital raise. Corvus successfully priced and closed an upsized public offering today, raising approximately $201 million. Investors responded positively to this move because it provides the company with a significant cash runway to fund upcoming Phase 2 and Phase 3 trials, effectively removing the immediate "cash burn" risk that often weighs on clinical-stage biotech stocks.

Get In Touch 📬

Help us deliver the best content possible by completing this brief survey. 📝

Want to see some change? Email Kevin Travers your feedback; follow him on Stocktwits.

Terms & Conditions 📝

Securities Disclaimer: STOCKTWITS IS NOT A TAX ADVISOR, BROKER, FINANCIAL ADVISOR OR INVESTMENT ADVISOR. THE SERVICE IS NOT INTENDED TO PROVIDE TAX, LEGAL, FINANCIAL OR INVESTMENT ADVICE, AND NOTHING ON THE SERVICE SHOULD BE CONSTRUED AS AN OFFER TO SELL, A SOLICITATION OF AN OFFER TO BUY, OR A RECOMMENDATION FOR ANY SECURITY. Trading in such securities can result in immediate and substantial losses of the capital invested. You should only invest risk capital, and not capital required for other purposes. You alone are solely responsible for determining whether any investment, security or strategy, or any other product or service, is appropriate or suitable for you based on your investment objectives and personal and financial situation. You should also consult an attorney or tax professional regarding your specific legal or tax situation. The Content is to be used for informational and entertainment purposes only and the Service does not provide investment advice for any individual. Stocktwits, its affiliates and partners specifically disclaim any and all liability or loss arising out of any action taken in reliance on Content, including but not limited to market value or other loss on the sale or purchase of any company, property, product, service, security, instrument, or any other matter. You understand that an investment in any security is subject to a number of risks, and that discussions of any security published on the Service will not contain a list or description of relevant risk factors. In addition, please note that some of the stocks about which Content is published on the Service have a low market capitalization and/or insufficient public float. Such stocks are subject to more risk than stocks of larger companies, including greater volatility, lower liquidity and less publicly available information. Read the full terms & conditions here. 🔍

Author Disclosure: The author of this newsletter does not hold positions in any of the securities or assets mentioned. 📋